Proton MR spectroscopic changes in Parkinson's diseases after thalamotomy

European Journal of Radiology

Volumn 47, Issue 3, 2003, Pages 179-187

  Baik, Hyun Man ^a   Choe, Bo Young ^a   Son, Byung Chul ^a   Jeun, Sin Soo ^a   Kim, Moon Chan ^a   Lee, Kwang Soo ^a   Kim, Bum Soo ^a   Lee, Jae Mun ^a   Lee, Hyoung Koo ^a   Suh, Tae Suk ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Metabolism; Parkinson's disease; Proton magnetic resonance spectroscopy; Thalamotomy

Indexed keywords

MAGNETIC RESONANCE SPECTROSCOPY; METABOLITES; PROTONS; SURGERY;

THALAMOTOMY;

RADIOLOGY;

ADULT; BRAIN METABOLISM; BRAIN REGION; CALCULATION; CLINICAL ARTICLE; CONFERENCE PAPER; EVALUATION; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; MEASUREMENT; METABOLIC RATE; OUTCOMES RESEARCH; PARKINSON DISEASE; PATIENT; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PUTAMEN; SPECTRUM; STEREOTAXIC SURGERY; STIMULATION; SUBSTANTIA NIGRA; THALAMOTOMY; THALAMUS; TREATMENT OUTCOME; TREMOR;

ADULT; ASPARTIC ACID; BRAIN; CHOLINE; CREATINE; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PARKINSON DISEASE; POSTOPERATIVE PERIOD; PROTONS; STEREOTAXIC TECHNIQUES; THALAMUS; TREATMENT OUTCOME; TREMOR;

EID: 10744233231     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0720-048X(02)00211-5     Document Type: Conference Paper

References (53)

1. Barbeau A. Six years of high-level levodopa therapy in severely akinetic parkinsonian patients. Arch. Neurol. 33:1976;333-338.
2. Boshes B., Arbit J., Dolkart M., et al. The sixth year after L-dopa: quality of life and insights derived. Trans. Am. Neurol. Assoc. 100:1975;166-168.
3. Delaney P., Fermaglich J. Parkinsonism and levodopa: a 5-year experience. J. Clin. Pharmacol. 16:1976;652-659.
4. Jankovic J., Cardoso F., Grossman R.G., Hamilton W.J. Outcome after stereotactic thalamotomy for parkinsonian, essential and other types of tremor. Neurosurgery. 37:1995;680-686.
5. Lang A.E., Lozano A.M., Montgomery E., Duff J., Tasker R., Hutchinson W. Posteroventral medial pallidotomy in advanced Parkinson's disease. New Engl. J. Med. 337:1997;1036-1042.
6. 15O PET study. Brain. 120:1997;1301-1313.
7. Davis K.D., Taub E., Houle S., et al. Globus pallidus stimulation activates the cortical motor system during allevation of parkinsonian symptoms. Nat. Med. 3:1997;671-674.
8. Limousin P., Greeene J., Pollak, Rothwell J., Benabid A.L., Frakowiak R. Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson's disease. Ann. Neurol. 42:1997;283-291.
9. Dogali M., Fazzini E., Kolodny E., et al. Stereotactic ventral pallidotomy for Parkinson's disease. Neurology. 45:1995;753-761.
10. Burchiel K.J. Thalamotomy for movement disorders. Neurosurg. Clin. North Am. 6:1995;55-71.
11. Fox M.W., Ahlskog J.E., Kelly P.J. Stereotactic ventrolateralis thalamotomy for medically tremor in post-levodopa era Parkinson's disease. Neurosurgery. 36:1995;1118-1127.
12. Atkinson J.D., Collins D.L., Bertrand G., Peters T.M., Pike G.B. Optimal location of thalamotomy lesions for tremor associated with Parkinson disease: a probabilistic analysis based on postoperative magnetic resonance imaging and an integrated atlas. J. Neurosurg. 96:(5):2002;854-866.
13. Goodman S.H., Wilkinson S., Overman J., et al. Lesion volume and clinical outcome in stereotactic pallidotomy and thalamotomy. Stereotactic Funct. Neurosurg. 71:(4):1998;164-172.
14. Holshouser B.A., Komu M., Moller H.E., et al. Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: a multicentre pilot study. Magn. Reson. Med. 33:1995;589-594.
15. Ellis C.M., Lemmens G., Williams S.C.R., Simmons A., et al. Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease. Neurology. 49:1997;438-444.
16. 1H magnetic resonance spectroscopy. Invest. Radiol. 33:1998;450-455.
17. Bottomley P.A. Spatial localization in NMR spectroscopy in vivo. Ann. New York Acad. Sci. 508:1987;333-348.
18. Hughes A., Daniel S., Kilford L., Lees A. Accuracy of clinical diagnosis of idiopathic Parkinsion's disease: a clinicopathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry. 55:1992;181-184.
19. Fahn S., Marsden C.D., Calne D.B., Goldstein M. Recent development in Parkinson's disease. 2:1987;153-163 Macmillan Health Care Information, Florham Park, NJ.
20. Fahn S., Marsden C.D., Calne D.B., Goldstein M. Recent development in Parkinson's disease. 2:1987;153-163 Macmillan Health Care Information, Florham Park, NJ.
21. Frahm J., Merbold K.D., Hanicke W. Localized proton spectroscopy using stimulated echoes. J. Magn. Reson. 72:1987;502-508.
22. Moonen C.T.W., van Zijl P.C.M. Highly effective water suppression for in vivo proton NMR spectroscopy (DRY STEAM). J. Magn. Reson. 88:1990;28-41.
23. 1H NMR chemical shift selective (CHESS) imaging. Phys. Med. Biol. 30:1985;431.
24. Doddrell D.M., Galloway G., Brooks W., Filed J., Bulsing J., Irving M., Baddeley H. Water signal elimination in vivo, using suppression by mistimed echo and repetitive gradient episodes. J. Magn. Reson. 70:1986;176-180.
25. 1H NMR spectroscopy in patients with chronic hepatic encephalopathy: analysis of change in cerebral glutamate, choline, and inositols. NMR Biomed. 4:1994;109-116.
26. Drayer B.P., Olanow W., Burger P., et al. Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron. Radiology. 159:1989;493-498.
27. Stern M.B., Braffman B.H., Skolnick B.E., et al. Magnetic resonance imaging in Parkinson's disease and Parkinsonian syndromes. Neurology. 39:1989;1524-1526.
28. Benabid A.L., Pollak P., Gao D., et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J. Neurosurg. 84:1996;204-214.
29. Goldman M.S., Ahlskog E., Kelly P. The symptomatic and functional outcome of stereotactic thalamotomy for medically intractable essential tremor. J. Neurosurg. 76:1992;924-928.
30. Jankovic J., Cardoso F., Grossman R., et al. Outcome after stereotactic thalamotomy for Parkinsonian, essential, and other types of tremor. Neurosurgery. 37:1995;680-687.
31. Nagaseki Y., Shibazaki T., Hirai T., et al. Long-term follow-up results of selective VIM-thalamotomy. J. Neurosurg. 65:1986;296-302.
32. 1H NMR spectroscopic studies of brain. Neurosci. Rev. 13:1989;23-31.
33. 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed. 4:1991;47-52.
34. Bruhn H., Frahm J., Gyngell M.L., Merboldt K.D., Hanicke W., Sauter R., Hamburger C. Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors. Radiology. 172:1989;541-548.
35. Langkowski J.H., Wieland J., Bomsdorf H., Leibfritz D., Westphal M., Offermann W., Maas R. Pre-operative localized in vivo proton spectroscopy in cerebral tumors at 4.0 T - first results. Magn. Reson. Imaging. 7:1989;547-555.
36. Gill S.S., Thomas D.G., Van Bruggen N., et al. Proton MR spectroscopy of intracranial tumors: in vivo and in vitro studies. J. Comput. Assist. Tomogr. 14:1990;497-504.
37. 1H NMR markers of neuronal and glial disorders. NMR Biomed. 2:1989;196-200.
38. Koller K.J., Zaczek R., Coyle J.T. N-acetyl-aspartyl-glutamate: regional levels in rat brain and the effects of brain lesions as determined by a new HPLC method. J. Neurochem. 43:1984;1136-1142.
39. Bruhn H., Frahm J., Gyngell M.L., Merboldt K.D., Hanicke W., Sauter R. Cerebral metabolism in man after acute stroke: new observations using localized proton NMR spectroscopy. Magn. Reson. Med. 9:1989;126-131.
40. Menon D.K., Baudouin C.J., Tomlinson D., Hoyle C. Proton MR spectroscopy and imaging of the brain in AIDS: evidence of neuronal loss in regions that appear normal with imaging. J. Comput. Assist. Tomogr. 14:1990;882-885.
41. Van Hecke P., Marchal G., Johannik K., Demaerel P., Wilms G., Carton H., Baert A.L. Human brain proton localized NMR spectroscopy in multiple sclerosis. Magn. Reson. Med. 18:1991;199-206.
42. Matthews P.M., Francis G., Antel J., Arnold D.L. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis. Neurology. 41:1991;1251-1256.
43. Kreis R., Ross B.D. Cerebral metabolic disturbances in patients with subacute and chronic diabetes mellitus: detection with proton MR spectroscopy. Radiology. 184:1992;123-130.
44. Ende G.R., Kaxer K.D., Knowlton R.C., et al. Temporal lobe epilepsy: bilateral hippocampal metabolic changes revealed at proton MR spectroscopic imaging. Radiology. 202:(3):1997;809-817.
45. Lu D., Pavlakis S.G., Frank Y., et al. Proton MR spectroscopy of the basal ganglia in healthy children and children with AIDS. Radiology. 199:1996;423-428.
46. Shonk T.K., Moats R.A., Gifford P., et al. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology. 195:1995;65-72.
47. Connelly A., Jackson G.D., Duncan J.S., King M.D., Gadian D.G. Magnetic resonance spectroscopy in temporal lobe epilepsy. Neurology. 44:1994;1411-1417.
48. Matthews P.M., Andermann F., Arnold D.L. A proton magnetic resonance spectroscopy study of focal epilepsy in humans. Neurology. 40:1990;985-989.
49. Brown B.C., Block R.E., Sanchez-Ramos J., et al. Proton MR spectroscopy of the brain in vivo in 14 patients with Parkinson's disease. Am. J. Neuroradiol. 16:1995;61-68.
50. Beal M.F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illness. Ann. Neurol. 31:1992;119-130.
51. Federico F., Simone I.L., Lucivero V., et al. Localized proton NMR spectroscopy in Parkinson's disease and progressive supranuclear palsy. J. Neurol. Neurosurg. Psychiatry. 62:1997;239-242.
52. Clarke C.E., Lowy M., Horsman A. Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy. Mov. Disord. 12:1997;297-301.
53. Davie C.A., Wenning G.K., Barker G.J., et al. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann. Neurol. 37:1995;204-210.